Chromatin Proteins and Transcription Factors as Therapeutic Targets

Erscheinungsjahr 2017
ISBN: 978-0-12-812390-4
Verlag: William Andrew Publishing

Buch, Englisch, 386 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 700 g

Chromatin Proteins and Transcription Factors as Therapeutic Targets, the latest volume in the Advances in Protein Chemistry and Structural Biology series is an essential resource for protein chemists. Each volume brings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.

Zielgruppe

Researchers and specialists in protein structure and interactions, cancer biology, psychiatry and mass spectrometry.

Autoren/Hrsg.

Weitere Mitwirkende

Donev, Rossen

Fachgebiete

• Naturwissenschaften Physik Angewandte Physik Biophysik
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Angewandte Biologie Biophysik
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. Targeting Chromatin Remodeling in Inflammation and Fibrosis2. HMGB1 Protein: A Therapeutic Target Inside and Outside the Cell3. Targeting IKK and NF-?B for Therapy4. NF-?B as a Therapeutic Target in Inflammatory-Associated Bone Diseases5. The Functional Stability of FOXP3 and ROR?t in Treg and Th17 and Their Therapeutic Applications6. The Complex Role of the ZNF224 Transcription Factor in Cancer7. Transcription Factors in Breast Cancer-Lessons From Recent Genomic Analyses and Therapeutic Implications8. Transcription Factors as a Target for Vaccination Against Ticks and Mites9. Elucidating the Mutational Landscape in Hepatocyte Nuclear Factor 1ß (HNF1B) by Computational Approach

Über Autor(innen)

Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.